Top

Published in:

01-03-2013 | Educational Series – Red Series

Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas

Authors: F. Calvo, C. Guillen Ponce, M. Muñoz Beltran, A. Sanjuanbenito Dehesa

Published in: Clinical and Translational Oncology | Issue 3/2013

Abstract

Borderline resectable pancreatic head carcinoma is a challenging disease that requires multidisciplinary approach to obtain maximal benefits from current therapeutical possibilities. We review current knowledge and therapeutic options for the patients from the surgical, medical oncology and radiotherapy views and emphasize the need for a coordinated multidisciplinary approach to obtain optimal results.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics 2010. CA Cancer J Clin 60:227–300CrossRef

Yeo CJ, Abrams RA, Grochow LB et al (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiotherapy improves survival. A prospective single institution experience. Ann Surg 225:621–633PubMedCrossRef

Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of respectable and borderline respectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733PubMedCrossRef

Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P (2010) Vascular invasion in pancreatic cancer. Imaging modalities preoperative diagnosis and surgical management. World J Gastroenterol 16(7):818–831PubMed

Soriano A, Castell A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA et al (2004) Preoperative staging and tumour resectability assessment of pancreatic cancer; prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol 99:492–501PubMedCrossRef

Baek SY, Sheafor DH, Keogan MT, DeLong DM, Nelson RC (2001) Two-dimensional multiplanar and three-dimensional volume-rendered vascular CT in pancreatic carcinoma: interobserver agreement and comparison with standard helical techniques. AJR Am J Roentgenol 176:1467–1473PubMed

Li H, Zeng MS, Zhou KR, Jin OY, Lou WH (2005) Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 29:170–175PubMedCrossRef

Lopez Hänninen E, Anithauer H, Hosten N et al (2002) Prospective evaluation of pancreatic tumours: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 224:34–41PubMedCrossRef

Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF (2000) Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 356:190–193PubMedCrossRef

10.

Varadarajulu S, Eloubiedi MA (2005) The role of endoscopic ultrasonography in the evaluation of pancreatico-biliary cancer. Gastrointest Endosc Clin N Am 15(3):497–511PubMedCrossRef

11.

Yussof IF, Meldenson RM, Edmuds SE et al (2003) Preoperative assessment of pancreatic malignancy using endoscopic ultrasound. Abdom Imaging 28:556–562CrossRef

12.

Sendler A, Avril N, Helmberger H et al (2000) Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 24:1121–1129PubMedCrossRef

13.

Sato E (2004) Pancreatic cancer imaging: which method? JOP 5:253–257

14.

Chang KJ (2006) EUS-guided fine-needle injection (FNI) and antitumour therapy. Endoscopy 38:s88–s93PubMedCrossRef

15.

Chang KJ (2006) State of the art lecture: endoscopic ultrasound and FNA in pancreatico-biliary tumours. Endoscopy 38(suppl):s56–s60PubMedCrossRef

16.

Boujaoude J (2007) Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol 13:3662–3666PubMed

17.

Jhala NC, Jhala D, Eltoum I et al (2004) Endoscopic ultrasound-guided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions. Cancer 102:239–246PubMedCrossRef

18.

Micames C, Jowel PS, White PR et al (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA versus percutaneous FNA. Gastrointest Endosc 58:690–695PubMedCrossRef

19.

Vollmer CM, Debrin JA, Middleton WD et al (2002) Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 235:1–7PubMedCrossRef

20.

Pisters PW, Lee JE, Vauthey JN et al (2001) Laparoscopy in the staging of pancreatic cancer. Br J Surg 88:325–337PubMedCrossRef

21.

Ahmed SI, Bochkarev V, Oleynikov D et al (2006) Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A 16:458–463PubMedCrossRef

22.

Warsaw AL, Gu ZY, Wittemberg J et al (1990) Preoperative staging and assessment of pancreatic cancer. Arch Surg 125:230–233CrossRef

23.

Andersson R, Vagianos CE, Williamson RCN (2004) Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6:5–12CrossRef

24.

Karachristos A, Sacrameas N, Hoffman JC (2005) CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 9:1286–1292PubMedCrossRef

25.

White R, Winston C, Gonem N et al (2008) Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 206:445–450PubMedCrossRef

26.

Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267PubMedCrossRef

27.

Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833–848PubMedCrossRef

28.

Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

29.

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRef

30.

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825PubMedCrossRef

31.

Ishii H, Furuse J, Boku N et al (2010) Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 40(6):573–579PubMedCrossRef

32.

Sahora K, Kuehrer I, Eisenhut A et al (2011) NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 149(3):311–320PubMedCrossRef

33.

Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M (2011) NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 35(7):1580–1589PubMedCrossRef

34.

Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509–3516PubMedCrossRef

35.

Rocha Lima CM, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 22(18):3776–3783PubMedCrossRef

36.

Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29(34):4548–4554CrossRef

37.

Kircher SM, Krantz SB, Nimeiri HS et al (2011) Therapy of locally advanced pancreatic adenocarcinoma unresectable and borderline patients. Exp Rev Anticancer Ther 11(10):1555–1565CrossRef

38.

Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64–76PubMedCrossRef

39.

Brunner TB, Grabenbauer G, Meyer T et al (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multicentre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7:41PubMedCrossRef

40.

Stessin AM, Meyer JE, Sherr DL (2008) Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 72(4):1128–1133PubMedCrossRef

41.

Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16(1):317–323PubMed

42.

Hoffman JP, Pendurthi TK, Ross E, Yeung RS (1998) Preoperative radiation therapy and chemotherapy for adenocarcinoma of the pancreas. Hepatogastroenterology 45(21):634–637PubMed

43.

Sasson AR, Wetherington RW, Hoffman JP et al (2003) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 34(2–3):121–128PubMedCrossRef

44.

Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89(2):314–327PubMedCrossRef

45.

Breslin TM, Hess KR, Harbison DB et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8(2):123–132PubMedCrossRef

46.

White RR, Xie HB, Gottfried MR et al (2005) Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12(3):214–221PubMedCrossRef

47.

Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496–3502PubMedCrossRef

48.

Golcher H, Brunner T, Grabenbauer G et al (2008) Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 34(7):756–764PubMedCrossRef

49.

Roy R, Maraveyas A (2010) Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist 15(3):259–269PubMedCrossRef

50.

Huguet F, André T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326–331PubMedCrossRef

51.

Brown KM, Siripurapu V, Davidson M et al (2008) Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 195(3):318–321PubMedCrossRef

52.

Krishnan S, Rana V, Janjan NA et al (2007) Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110(1):47–55PubMedCrossRef

53.

Landry J, Catalano PJ, Staley C et al (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101(7):587–592PubMedCrossRef

54.

Pedrazzoli S, Di Carlo V, Dionigi R et al (1998) Standard vs extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter prospective randomized study. Lymphadenectomy study group. Ann Surg 228:508–517PubMedCrossRef

55.

Nimura Y, Nagino M, Kato H et al (2004) Regional vs extended lymphadenectomy for pancreatic cancer. A multicenter randomized controlled trial. HPB 6:2

56.

Yeo CJ, Cameron JL, Sohn TA et al (1999) Pancreatoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short term outcome. Ann Surg 229:613–622PubMedCrossRef

57.

Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreatoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 236:355–366PubMedCrossRef

58.

Nguyen TC, Sohn TA, Cameron JL et al (2003) Standard vs radical pancreatoduodenectomy for periampullary adenocarcinoma a prospective randomized trial evaluating quality of life in pancreatoduodenectomy survivors. J Gastrointest Surg 7:1–9PubMedCrossRef

59.

Riall TS, Cameron JL, Lillemoe KD et al (2005) Pancreatoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma part 3: update on 5-year survival. J Gastrointest Surg 9:1191–1204PubMedCrossRef

60.

Farnell MB, Pearson RK, Sarr MG et al (2005) A prospective randomized trial comparing pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in respectable pancreatic head carcinoma. Surgery 138:618–628PubMedCrossRef

61.

Fortner JG (1973) Regional resection of cancer of the pancreas a new surgical approach. Surgery 73:307–320PubMed

62.

Tseng JF, Raut CP, Lee JE et al (2004) Pancreatoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8:935–949PubMedCrossRef

63.

Raut CP, Tseng JF, Sun CC et al (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52–56PubMedCrossRef

64.

Al-Haddad M, Martin JK, Nguyen J et al (2007) Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg 11:1168–1174PubMedCrossRef

65.

Siriwardana HP, Siriwardena AK (2006) Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 93:662–673PubMedCrossRef

66.

Horio T, Sugiura Y, Aiko S et al (2009) Pancreatectomy for pancreatic cancer with reference to combined resection of the vessels, twenty nine year experience by a single surgeon. Keio J Med 58:103–109PubMedCrossRef

67.

Stitzenberg KB, Watson JC, Roberts A et al (2008) Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 15:1399–1406PubMedCrossRef

68.

Nakao A, Takeda S, Inoue S et al (2006) Indications and techniques of extended resection for pancreatic cancer. World J Surg 30:976–982PubMedCrossRef

69.

Baulieux J, Adham M, Oussoultzoglou E et al (1998) La pancreatectomie pour cancer avec résection des vaisseaux rétropancreatiques est-elle justifiée? Ann Chir 123:438–444

70.

Martin RC, Scoggins CR, Egnatashvili V et al (2009) Arterial and venous resection for pancreatic adenocarcinoma. Arch Surg 144:154–159PubMedCrossRef

71.

Miller RC, Valentini V, Moss A et al (2010) Pancreas cancer. In: Gunderson LL, Willett CG, Calvo FA, Harrison LB (eds) Intraoperative irradiation, 2nd edn. Springer/Humana Press, New York, pp 249–271

72.

Sindelar WF, Kinsella TJ (1999) Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 4:226–230CrossRef

73.

Ruano-Ravina A, Almazán R, Guedea F (2008) Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 87:318–325PubMedCrossRef

74.

Valentini V, Calvo FA, Reni M et al (2009) Intraoperative radiotherapy in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol 91:54–59PubMedCrossRef

75.

Calvo FA, Valentini V (2008) Radiotherapy for pancreatic cancer: systematic nihilism of intraoperative realismo. Radiother Oncol 87:314–317PubMedCrossRef

76.

Greer SE, Pipas JM, Sutton JE et al (2008) Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 206(3):451–457PubMedCrossRef

77.

Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899–903PubMedCrossRef

78.

(1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumour Study Group. Cancer 59(12):2006–2010

79.

Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230(6):776–782PubMedCrossRef

80.

Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 358(9293):1576–1585PubMedCrossRef

81.

Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210PubMedCrossRef

82.

Stocken DD, Buchler MW, Dervenis C et al (2005) Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 92(8):1372–1381PubMedCrossRef

83.

Hsu CC, Herman JM, Corsini MM et al (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 17(4):981–990PubMedCrossRef

84.

Demols A, Peeters M, Polus M et al (2005) Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys 62(5):1351–1356PubMedCrossRef

85.

Wilkowski R, Thoma M, Duhmke E, Rau HG, Heinemann V (2004) Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 58(3):768–772PubMedCrossRef

86.

Blackstock AW, Mornex F, Partensky C et al (2006) Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 95(3):260–265PubMedCrossRef

87.

Regine WF, Winter KA, Abrams R et al (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18(5):1319–1326PubMedCrossRef

88.

Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomized multicentre study. Eur J Cancer 29A(5):698–703PubMedCrossRef

89.

Takada T, Amano H, Yasuda H et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A Phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95(8):1685–1695PubMedCrossRef

90.

Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277PubMedCrossRef

91.

Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081PubMedCrossRef

Title: Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas
Authors: F. Calvo
C. Guillen Ponce
M. Muñoz Beltran
A. Sanjuanbenito Dehesa
Publication date: 01-03-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 3/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0962-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Viruses in cancer treatment

Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009

Effectiveness of oxaliplatin desensitization protocols

Identification of valid reference housekeeping genes for gene expression analysis in tumor neovascularization studies

Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma

Novel insight into the role of GAPDH playing in tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer